← Back to Screener
XBiotech Inc (XBIT)
Price$2.37
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-3.52%
Price vs S&P 500 (4W)-3.65%
VGM Score54.93
Market Capitalization$72.87M
All Metrics
Book Value / Share (Quarterly)$4.43
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.39
Price vs S&P 500 (YTD)-8.99%
Gross Margin (TTM)83.79%
Net Profit Margin (TTM)-820.45%
EPS (TTM)$-1.32
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-1.32
EPS (Annual)$-1.30
ROI (Annual)-20.26%
Gross Margin (Annual)83.79%
Cash / Share (Quarterly)$3.79
ROA (Last FY)-19.59%
EBITD / Share (TTM)$-1.54
ROE (5Y Avg)-11.20%
Operating Margin (TTM)-860.10%
Cash Flow / Share (Annual)$-1.32
P/B Ratio0.54x
P/B Ratio (Quarterly)0.53x
Net Income / Employee (Annual)$-458,800
EV / Revenue (TTM)-10.62x
Net Interest Coverage (TTM)-105.08x
ROA (TTM)-25.06%
EV / EBITDA (TTM)-0.06x
EPS Incl Extra (Annual)$-1.30
Current Ratio (Annual)16.01x
Quick Ratio (Quarterly)38.60x
3-Month Avg Trading Volume0.03M
52-Week Price Return-17.13%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)18.17x
Asset Turnover (Annual)0.02x
52-Week High$3.61
EPS Excl Extra (Annual)$-1.30
CapEx CAGR (5Y)-40.04%
26-Week Price Return4.41%
Quick Ratio (Annual)15.88x
13-Week Price Return2.60%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)39.03x
Enterprise Value$-42.59M
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-17.30%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-837.66%
Cash / Share (Annual)$4.12
3-Month Return Std Dev24.32%
Net Income / Employee (TTM)$-472,500
ROE (Last FY)-21.40%
Net Interest Coverage (Annual)-24.03x
EPS Basic Excl Extra (Annual)$-1.30
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.32
Receivables Turnover (Annual)0.00x
ROI (TTM)-26.10%
P/S Ratio (TTM)18.17x
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-41.50%
Year-to-Date Return-0.84%
5-Day Price Return-0.42%
EPS Normalized (Annual)$-1.30
ROA (5Y Avg)-10.66%
Net Profit Margin (Annual)-820.45%
Month-to-Date Return-2.07%
EBITD / Share (Annual)$-1.34
Operating Margin (Annual)-860.10%
ROI (5Y Avg)-10.97%
EPS Basic Excl Extra (TTM)$-1.32
P/B Ratio (Annual)0.51x
Pretax Margin (TTM)-837.66%
Book Value / Share (Annual)$4.60
Price vs S&P 500 (13W)-5.66%
Beta0.84x
P/FCF (Annual)1.11x
Revenue / Share (TTM)$0.00
ROE (TTM)-26.10%
52-Week Low$2.09
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Sep 2021
Oct 2021
Nov 2021
Dec 2021
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XBITXBiotech Inc | — | — | C | $2.37 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
XBiotech is a clinical-stage biopharmaceutical company developing monoclonal antibodies using its proprietary True Human technology platform. The company focuses on anti-inflammatory therapeutic antibodies, primarily for oncology applications. All operations are based in the United States.